General Motors' Profit Jumps 34% on Strong SUV and Truck Demand
Despite increasing market pressures, GM generated strong profits in both the U.S. and China.
Twitter's First Quarter Was Good. Instagram's Was Better.
Instagram now has 700 million monthly users. More than twice as many as Twitter.
Amazon's Cloud Business Continues to Overshadow E-Commerce
Cloud infrastructure is going to get a whole lot more competitive.
Markel Offers a Deceptively Good Quarter
The specialty insurer's underwriting operations took an unusual hit in Q1 while its other businesses picked up the slack.
It would also save Medicare nearly $500 million annually.
The company reported improving sales, but pricing and operating margin conditions remain challenging.
Dave & Buster's and Planet Fitness are both bucking the brick-and-mortar trends. Here's how they could benefit from retail pain.
In a battle between two content giants, it's the "other" businesses that decide the winner.
The embedded system solutions company exceeded expectations yet again in the first quarter. Here's what investors need to know.
Investments that can stand the test of time are invaluable.
Will General Motors win the self-driving car race?
Most retail investors who look at alternative asset managers see complexity, high fees, and wildly variable payouts, and shy away -- but some may see opportunity.
Tesla plans to double the number of Superchargers during 2017. Yet that won't fend off congestion problems for very long.
American teenagers command $44 billion in direct annual spending power, and the demographic has a huge fondness for video games.
It depends on where they live.
You may be surprised at how much an early 401(k) withdrawal could affect you.
If it doesn't get one, it may be forced to "go to war with the destroyers it has -- not the destroyers it might want or wish to have at a later time."
Efficiency is a big differentiator in solar, so who leads the pack among the industry's leaders?
The slack motorcycle industry may cause bike shipments -- and sales -- to be lower than expected.
The FDA has approved Dupixent for moderate to severe eczema, and it has accepted the company's resubmission of sarilumab for rheumatoid arthritis. These drugs could give shares the shot in the arm they need.
The investment and financial services software company dropped despite beating expectations and increasing guidance. Here's what investors need to know.
This REIT has a fantastic track record of delivering market-beating returns and strong dividend growth.
Trumpcare version 2.0 is great for insurers and bad news for the consumer.
This figure is shocking, but for all the wrong reasons.